MRK dividend yield: 3.25%. QYLD dividend yield: 11.43%. Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s. QYLD sells covered calls on the full Nasdaq 100 index, generating very high monthly income (10%+ yield). The strategy caps upside participation in exchange for income. Best suited for investors who prioritize maximum current income over capital appreciation. NAV erosion over time is a known trade-off.
Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.
QYLD sells covered calls on the full Nasdaq 100 index, generating very high monthly income (10%+ yield). The strategy caps upside participation in exchange for income. Best suited for investors who prioritize maximum current income over capital appreciation. NAV erosion over time is a known trade-off.
Is MRK or QYLD better for dividend income in 2026?
MRK currently offers a 3.25% yield (3.08/share/year) while QYLD offers 11.43% (1.92/share/year). QYLD provides higher current income. However, MRK has grown its dividend faster (8.2% 5Y CAGR), which may lead to better long-term income through compounding.
How much would $10,000 in MRK vs QYLD earn per year?
With $10,000 invested today: MRK pays approximately $325/year. QYLD pays approximately $1143/year. With DRIP reinvestment over 10 years, these grow to $950/year (MRK) and $3,554/year (QYLD).
Does MRK or QYLD pay monthly dividends?
MRK pays quarterly dividends. QYLD pays monthly dividends. QYLD pays monthly, which is preferred by investors who need regular cash flow.
📬
Get this MRK vs QYLD comparison by email
Save your analysis + get weekly dividend insights. Free forever.